NR1D2 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-27. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
==== Iron ==== Iron is stored as iron(III) in ferritin. The exact nature of the binding site has not yet been determined. The iron appears to be present as a hydrolysis product such as FeO(OH). Iron is transported by transferrin whose binding site consists of two tyrosines, one aspartic acid and one histidine. The human body has no controlled mechanism for excretion of iron. This can lead to iron overload problems in patients treated with blood transfusions, as, for instance, with β-thalassemia. Iron is actually excreted in urine and is also concentrated in bile which is excreted in feces.
== Research == Degarelix is studied for use as a chemical castration agent on men with pedophilia in Sweden. A study demonstrated a reduced risk score for committing child sexual abuse in men with pedophilic disorder two weeks after initial injection.
== Faculty Positions == On the faculty of Indiana University, Bloomington, since 1971. 1978 – Professor of Chemistry. 1980 – Visiting Scientist, Department of Immunogenetics, Max Planck Institute for Biology, Tübingen, Germany. 1988 – James H. Rudy Professor of Chemistry. 1999 – Distinguished Professor of Chemistry. 1999 – Director of the Institute for Pheromone Research. 2000–2015 – Lilly Chemistry Alumni Chair. 2004 – Adjunct Professor of Medicine, Indiana University School of Medicine. 2004–2009 – Director of the National Center for Glycomics and Glycoproteomics. 2010 – Director of the Novotny Glycoscience Laboratory. 2011 – Distinguished Professor Emeritus of Chemistry.
Sources: en.wikipedia.org
An FC soldier was slightly injured in a drone attack on a post in Bannu District. A soldier from Sindh Regiment was killed in an engagement with militants near the border in Orakzai District. Five personnel from a Bomb Disposal Unit were killed in a militant attack in North Waziristan. A soldier was injured in an IED explosion in Karak District. Eight TTP militants were killed in a military IBO in Dosali. On 22 June, an insurgent commander was killed at South Waziristan-Chaman border. On 23 June, a civilian was injured in a militant drone strike on a rickshaw in Bannu District, while an FC soldier and a sweeper at a police station were abducted, the Bannu cantonment was hit twice with mortar shells. A government school in South Waziristan was destroyed by militants. Several artillery and mortar shells fired from Afghanistan hit Angoor Adda and Zalol Khel, two unexploded shells were also recovered from Bajaur District. On 24 June, a school in South Waziristan was destroyed by insurgents. Eight policemen including an SHO were abducted from South Waziristan. CTD killed six TTP militants in an operation in Lower Dir. Four TTP militants were killed in an operation near Miramshah and four more in Tank District whereas a TTP attack in Hangu District was repulsed, a soldier also died in the operation in Tank District. A quadcopter strike on a police station in Bannu District wounded two policemen whereas a school headmaster was also abducted from the district. An airstrike in South Waziristan killed two TTP insurgents.
General statistics indicate that 70–80 percent of women require direct clitoral stimulation (consistent manual, oral, or other concentrated friction against the external parts of the clitoris) to reach orgasm. Indirect clitoral stimulation (for example, by means of vaginal penetration) may also be sufficient for female orgasm. The area near the entrance of the vagina (the lower third) contains nearly 90 percent of the vaginal nerve endings, and there are areas in the anterior vaginal wall and between the top junction of the labia minora and the urinary meatus that are especially sensitive, but intense sexual pleasure, including orgasm, solely from vaginal stimulation is occasional or otherwise absent because the vagina has significantly fewer nerve endings than the clitoris. The prominent debate over the quantity of vaginal nerve endings began with Alfred Kinsey. Although Sigmund Freud's theory that clitoral orgasms are a prepubertal or adolescent phenomenon and that vaginal (or G-spot) orgasms are something that only physically mature females experience had been criticized before, Kinsey was the first researcher to harshly criticize the theory. Through his observations of female masturbation and interviews with thousands of women, Kinsey found that most of the women he observed and surveyed could not have vaginal orgasms, a finding that was also supported by his knowledge of sex organ anatomy. Scholar Janice M.
== Treatment == There is no distinct treatment option that can undo the effects and damage from rhabdomyolysis because it is a type of necrosis, where the tissue and body cells die prematurely. However, the rate of the pathology that can lead to more complications can be decreased by acting early and consistently. Overall treatment depends on preventing kidney failure (renal failure) which is done by rehydrating the patient. It also depends on making urine have a more basic pH (alkalinization of urine).
Sources: en.wikipedia.org
Thus an antigen might bind specifically to a T or B cell receptor, but not induce an adaptive immune response. If the antigen does induce a response, it is an 'immunogenic antigen', which is referred to as an immunogen.
Between 2011 and 2014, Stick Men and Adrian Belew's Power Trio band (Belew plus drummer Tobias Ralph and bass player Julie Slick) joined forces to play and tour as The Crimson ProjeKCt, covering the music made during the '80s and '90s. Following the return of King Crimson in 2014, the Crimson ProjeKct name has been formally abandoned, but the Stick Men and the Power Trio have still performed together from time to time, usually under names like "Belew, Levin, Mastelotto and friends". During his solo career, including performances with the Power Trio, Adrian Belew has performed various versions of King Crimson songs. In March 2024, a new spin-off supergroup called Beat performing the 1980s King Crimson repertoire was announced: this featured former members Adrian Belew and Tony Levin along with guitarist Steve Vai and drummer Danny Carey of Tool. Fripp and Bruford had both declined offers to join, but gave their blessings to the group. Fripp also suggested the eventual project name, "Beat" (after the 1982 King Crimson album). The band went on to tour the United States during the latter half of 2024.
== Family sphere == Women in France perform approximately 64% of household labor. Between 1966 and 1986, men's participation in domestic tasks increased slightly but has remained largely unchanged since. Task distribution becomes more unequal in households with two or more children, with men's involvement decreasing by about 10%. A study by INED reports that 30% of men primarily manage household chores; however, this figure does not include the 15% of children involved in family court proceedings following separation, in which fathers may take on increased caregiving and domestic responsibilities. According to a 2010 INSEE study, women spend an average of 3 hours and 26 minutes per day on domestic tasks, compared to 2 hours for men. Child custody is contested in approximately 18% of divorces. In about 90% of cases, custody is awarded to the mother, with few fathers requesting custody. Custody is awarded to fathers in about 8% of cases. Post-divorce, women experience a greater decline in standard of living compared to men. Following separation, approximately one-third of women and one-half of men enter new partnerships. Shared custody arrangements are becoming more common and now account for about 10% of divorce cases.
It is, in some countries, sold already chopped or diced. Mutton barbeque is a tradition in Western Kentucky. The area was strong in the wool trade, which gave them plenty of older sheep that needed to be put to use.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.